Peripheral administration of an IL-1β receptor antagonist is protective in both transient and permanent middle cerebral artery occlusion models of stroke [33,34,35], and the IL-1β antibody, canakinumab, was shown to be protective in strokes in a clinical trial [15]. The gene discussed is IL1B; the disease is stroke disorder.